

ASX Release

SUDA LTD BUSINESS DEVELOPMENT UPDATE

PERTH, AUSTRALIA – 17 November 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it is on track with its business development goals to sign licensing deals in FY2015/16 and to secure philanthropic funding for a second Phase III study of ArTiMist™ in paediatric malaria.

In early November, the management team attended the BIO-Europe international partnering conference, which was held in Munich, Germany; and also the Northern Australian Investment Forum on tropical diseases, which took place in Darwin. These events provided excellent opportunities for the Company to further advance its business development activities.

SUDA's business development team met with 41 companies at the BIO-Europe event, comprising 24 first-time meetings and 17 ongoing dialogues with prospective partners. The most advanced discussions are at the stage of financial negotiation and span several of the companies' first-in-class oral sprays in various territories.

The invitation-only Northern Australia Investment Forum was attended by senior executives from the pharmaceutical industry, including the companies that are currently evaluating SUDA's ArTiMist™ sublingual anti-malarial spray. In addition to meeting with its potential partners, SUDA also presented the proposed trial design of ArTiMist™ in the pre-referral setting to several global health philanthropic funds. There was strong engagement and interest from these groups to provide non-dilutive funding to support the proposed study, which is designed to evaluate ArTiMist™ compared to intra-rectal artesunate suppositories as an early interventional treatment of paediatric malaria in the pre-referral setting.

Following these events, the Company has increased the number of pharmaceutical companies that it has interacted with to 196 since commencing its outreach to the industry in March 2014. Over 30 of these companies have signed confidentiality agreements and are at various stages of due diligence or term sheet negotiations.

Commenting on SUDA's business development progress, Mr Stephen Carter, Chief Executive Officer of SUDA said: "We are working hard to achieve our business development goals for FY2015/16. We have many sets of discussions that have reached an advanced stage, spanning several products and territories. Hence, we remain confident in our strategy and operational direction. I look forward to announcing a series of out-licensing deals in due course. Furthermore, I am delighted by the reception we received from philanthropic funds that are interested in supporting an expansion of the use of ArTiMist™ to treating paediatric malaria in the pre-referral setting."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au